After intravenous administration of tofacitinib to G-ARF and C-ARF rats, its AUC was significantly higher than that in control rats due to a significantly lower CLNR (due to a decrease in the protein expressions of the hepatic CYP3A1/2 and CYP2C11 subfamily) and CLR (due to a significantly lower CLCR by an impaired kidney function) than in control rats. The gene discussed is CTRC; the disease is acute kidney injury.